Gregoire Schwach joined Re-Vana in 2023 as Head of Biologics. He has extensive experience in drug product development with expertise in Biologics, Drug Delivery and CMC. He transitioned from Roche, Switzerland, where he led the drug product development of the biologics ocular pipeline. His team was instrumental in the approval of Vabysmo®, and he established the SusvimoTM port delivery implant technology in Basel. Prior to Roche, Gregoire worked for Ferring, Denmark, as director of early stage development and as CMC project leader of Firmagon®. Gregoire has also a very strong expertise in Polymer Science and Medical Devices. He has worked for Phusis, France, as head of polymer development, supporting the approval of Phusiline® bioerodible interference screws used in ACL reconstruction. He is educated as Chem Eng from INSA Rouen, with MPhil, PhD from the University of Montpellier, France, and postdoc fellowship at the School of Pharmacy of Geneva, Switzerland.